STAT+: A lawsuit over a controversial Sanofi drug shortage is unexpectedly revived
A U.S. appeals court revived a controversial lawsuit brought by nearly two dozen people who…
Category: STAT+
STAT+: As regulators play catch up with AI, tech startups say uncertainty is slowing them down
The federal government’s plan to boost its oversight of the use of artificial intelligence tools…
STAT+: Obamacare plans don’t have to cover weight loss drugs. The government is considering changing that
WASHINGTON — Drugmakers are doing everything to tap the bottomless well of demand for new…
STAT+: Opioid cravings were reduced by anti-obesity drug in small study
DENVER — The GLP-1 medication liraglutide significantly reduced opioid cravings in a small analysis presented on…
STAT+: Leading MD Anderson oncologist disputes junior scientist’s claims in lawsuit over research credit
Prominent immunologist and oncologist Padmanee Sharma defended herself in court on Friday against a lawsuit…
STAT+: In ‘major milestone,’ FDA approves first cell therapy for solid tumors
Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests…
STAT+: Banning surprise medical bills is raising costs elsewhere
Without question, the new federal law banning surprise billing is achieving its goal of protecting…
STAT+: Flagship Pioneering startup lays off a third of staff
Sonata Therapeutics, a startup created two years ago through the merger of two Flagship Pioneering…
STAT+: Medicare Advantage enrollment races past 33 million
Roughly 33.4 million adults older than 65 and people with disabilities were enrolled in a…
STAT+: Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech
CAMBRIDGE, Mass. — The increasingly adversarial relationship between the United States and China has raised…
STAT+: Pharmalittle: We’re reading about kids taking Wegovy, telehealth for abortion pills, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: For unlucky mountaineers, tundra explorers and the unhoused, a new drug could avert the ravages of frostbite
Two days after his right hand froze, Hart Bezner realized for the first time that…
STAT+: FDA cracks down on websites that claim to sell chemicals in obesity drugs Wegovy, Zepbound
The Food and Drug Administration is cracking down on websites that claim to sell the…
STAT+: Sick patients collapsed waiting for care at Mass. hospital with known safety violations
Struggling to breathe, the patient stepped out of the registration line in the hospital’s overwhelmed…
STAT+: Hospital claims it was ‘drastically’ overcharged by pharma in a federal drug discount program
For several years, some of the world’s largest pharmaceutical companies that participate in a U.S….
.jpg)
STAT+: Pharmalittle: We’re reading about a FTC probe into GPOs, a frostbite drug, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
.jpg)
STAT+: Gaming Amylyx stock reactions to the next ALS drug test, and a chat with CRISPR’s CEO about a new investor
This week, a preview of the TUDCA study in ALS and thoughts on how it…
STAT+: Leaked version of EFTA-India free trade deal sparks alarm over access to medicines
A leaked version of a proposed agreement between India and the European Free Trade Association…
STAT+: The Jewish American and Palestinian American scientists who’ve been partnering for 14 years on science’s toughest challenges
WATERTOWN — Their brainstorming began in an MIT class in 2010 when the eager undergrads…
STAT+: FTC to probe the role of middlemen in worsening drug shortage crisis
The Federal Trade Commission is launching a probe into the extent to which group purchasing…
STAT+: Digital tools helped lower blood pressure in marginalized patient groups
If you have high blood pressure, it’s increasingly likely that your doctor or your insurer…
STAT+: Pharmalittle: We’re reading about slow uptake of an Alzheimer’s drug, an opioid lawsuit, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Biotech launches with $135 million for Vertex-competing pain medicine
After three years being incubated by California VC Westlake Village BioPartners, a new biotech launched…
Opinion: STAT+: A year in, the U.S. is still not taking advantage of lower-cost biosimilars for Humira
It’s been one year since the launch of the first adalimumab biosimilar for Humira in…
STAT+: FDA advisory panel votes in favor of Abbott’s new heart device
An advisory panel to the Food and Drug Administration voted in favor of a new…
STAT+: Lawmakers eye partial increase for Medicare doctor pay
WASHINGTON — Lawmakers are considering increasing doctors’ Medicare pay in an upcoming government funding package,…
STAT+: Private equity investment in Medicare Advantage drops
Major insurance companies like UnitedHealthcare and Humana have edged out private equity firms from investing…
STAT+: Pharmalittle: We’re reading about a tossed PhRMA lawsuit, secrecy clauses, and more
Rise and shine, everyone, another busy day is on the way. However, the pace this…
STAT+: Startup BioAge raises $170 million Series D for Zepbound combination therapy
A California biotech developing a combination therapy with the obesity drug Zepbound has raised a…
STAT+: KalVista pill reduces swelling symptoms caused by genetic disease, achieving goal of late-stage study
KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced…
Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability
The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate…
STAT+: Judge tosses PhRMA lawsuit over Medicare power to negotiate drug prices
WASHINGTON — A federal district judge on Monday granted the Biden administration’s request to dismiss…
STAT+: Gilead to acquire CymaBay for $4.3 billion, adding new treatment for liver disease
Gilead Sciences said Monday it will acquire CymaBay Therapeutics for $4.3 billion, adding a new…
STAT+: Pharmalittle: We’re reading about Moderna’s RSV vaccine, Aurobindo problems, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: A flurry of research misconduct cases has universities scrambling to protect themselves
There was a time when an allegation of data mishandling, scientific misconduct, or just a…
STAT+: States are ramping up scrutiny of health transactions, as more provider groups look for buyers
UnitedHealth Group’s Optum has bought an untold number of physician practices over the years. It…
STAT+: FTC doubles down in Welsh Carson anesthesia case to limit private equity’s physician buyouts
Lina Khan’s Federal Trade Commission is eager to make Big Physician a lot smaller. Last…
STAT+: Major generic maker Aurobindo cuts production at a key plant amid concerns over shortages
Aurobindo, which is one of the largest generic drug makers, has halted some production at…
STAT+: Senators start work on Medicare physician payment reform
WASHINGTON — A bipartisan group of senators is starting work on legislation to reform how…
STAT+: Pharmalittle: We’re reading about a U.S. vaccine panel, an abortion pill, and much more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Lasers, cardiology, clinical trials: 2023’s top private equity targets
By some measures, private equity investment lagged in 2023, a year marked by growing distress…
STAT+: A junior scientist. A prominent oncologist. Now, a clash at MD Anderson over who gets research credit
Three years ago, Jamie Lin, an early-career nephrologist at MD Anderson Cancer Center, made findings…
STAT+: Key House Republican on health care plans exit from Congress
WASHINGTON — Rep. Cathy McMorris Rodgers, the chair of a crucial House committee that handles…
STAT+: Senate Democrats push for stronger rules around AI in Medicare Advantage
Senate Democrats on Thursday said Medicare should take more urgent and aggressive action to prevent…
In a showy hearing, Bernie Sanders gets few answers about lower drug prices
WASHINGTON — Call it Sen. Bernie Sanders’ prescription drug pricing theater. The hearing, featuring Merck…
STAT+: A looming cancer vaccine test for Gritstone Bio, and pushback about Novartis-MorphoSys
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview…
STAT+: A looming cancer vaccine test for Gristone Bio, and pushback on my Novartis-MorphoSys take
This week, I address pushback I received on my Novartis-MorphoSys column. But first, a preview…
STAT+: Pharmalittle: We are reading about Catalent concerns, a congressional hearing, and more
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: As Medicare drug pricing negotiations begin, AstraZeneca stays mum on government’s offer
LONDON — Medicare’s first-ever drug pricing negotiations are officially underway. But neither government officials nor…
STAT+: More than half the slots on a key vaccine advisory panel are vacant. Where’s HHS?
A critical government advisory committee charged with charting U.S. vaccination policy appears to be atrophying,…